Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of maridebart cafraglutide in obesity or overweight with type 2 diabetes mellitus
2025-524788-19-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Oct 2026
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing Maridebart cafraglutide with Placebo (2 arms). Primary endpoints: Percent change from parent-trial baseline in body weight and Treatment-emergent adverse events and serious adverse events. Planned start Oct 2026; status: authorised.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-524788-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524788-19-00.